← Human Trials & Peer-Reviewed Studies
Effect of cholecalciferol supplementation on hand grip strength, walking speed, and expression of vitamin D receptor, interleukin-6, and insulin-like growth factor-1 in monocyte in pre-frail older adults: A randomized double-blind placebo-controlled trial
Plain-language guide to PMID 38644647 (2024): double-blind randomized controlled trial study of IGF-1 LR3.
Key Facts
- PMID
- 38644647
- Journal
- Geriatrics & gerontology international
- Year
- 2024
- Study type
- Randomized Controlled Trial
- Authors
- Dwimartutie N et al. (10 authors)
- DOI
- 10.1111/ggi.14881
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of IGF-1 LR3, published as a randomized controlled trial.
To investigate the effect of cholecalciferol supplementation on hand grip strength, walking speed, and expression of vitamin D receptor (VDR), interleukine-6 (IL-6) and insulin-like growth factor-1 (IGF-1) in monocyte in pre-frail older adults.
Who Took Part
PubMed indexes the participants as older adults and people over 80, both men and women.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
The participants were allocated by chance, so the IGF-1 LR3 group and the comparison group should start out alike.
Neither the participants nor the staff measuring them knew who was on IGF-1 LR3, so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with IGF-1 LR3 could be set against what happens without it.
Hand grip strength and walking speed, as primary outcomes, were analyzed using intention-to-treat analysis.
The expression of VDR, IGF-1 and IL-6 in monocytes, as secondary outcomes, were analyzed using per-protocol analysis.
What Was Measured
PubMed files the paper under topics including Hand Strength, Interleukin-6, Cholecalciferol, Monocytes, Receptors, Calcitriol, Dietary Supplements and Insulin-Like Growth Factor I.
The authors tagged it with the keywords hand grip strength, pre‐frail older adult and walking speed.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of IGF-1 LR3.
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2024 (Geriatrics & gerontology international), a journal based in Japan.
More context: the IGF-1 LR3 compound page, all human trials.
Our Notes on the Compound
IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.